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Summary
 
The murine interleukin 4 receptor (IL-4R) exists as a transmembrane protein transducing
pleiotropic IL-4 functions, or as soluble (s)IL-4–binding molecule with potent immunoregula-
tory effects. In this study we identified and characterized a murine IL-4R allotype. Sequence
analysis of the IL-4R cDNA of BALB/c mice revealed 18 base substitutions leading to three
extracellular and five cytoplasmic amino acid changes when compared with the published IL-4R
sequence of C57BL/6 mice. Analyses with allotype-specific mAbs revealed that AKR/J and
SJL/J mice possess the newly identified BALB/c IL-4R allotype whereas the IL-4Rs of C3H,
CBA, DBA-2, and FVB/N mice are identical to that of the C57BL/6 mouse. The extracellular
Thr49 to Ile substitution abrogates one 
 
N
 
-glycosylation site in the naturally occurring BALB/c
IL-4R as well as in the experimentally point mutated C57BL/6-T49I sIL-4R, and both mole-
cules display a nearly threefold reduction in IL-4–neutralizing activity compared to the
C57BL/6 sIL-4R. In line with this, a significantly enhanced dissociation rate of IL-4 was de-
tected for the BALB/c IL-4R allotype by surface plasmon resonance and in radioligand binding
studies with IL-4R–transfected cell lines. These findings suggest that the altered ligand binding
behavior of the newly described IL-4R allotype may influence the IL-4 responsiveness, thus
contributing to the diverse phenotypes of inbred mouse strains in IL-4–dependent diseases.
 
I
 
nterleukin 4 (IL-4) is a multifunctional cytokine pro-
duced by T cells, mast cells, and basophils (for review see
reference 1). On B cells IL-4 stimulates proliferation and
differentiation, induces the expression of MHC II mole-
cules as well as CD23, and is indispensable for the Ig heavy
chain class switching to IgE in mice (for review see refer-
ence 2). Cells of the monocytic lineage display enhanced
levels of MHC II molecules correlating with an increased
antigen-presenting function of macrophages, whereas the
production of proinflammatory cytokines is downregulated
in the presence of IL-4 (for review see reference 3). In the
T cell compartment, IL-4 is required for the development
of Th2, which was demonstrated by the use of anti–IL-4
strategies such as neutralizing Abs (4, 5), soluble (s)IL-4
 
1
 
 re-
ceptors (6, 7), or IL-4 gene deficient mice (8) in a variety
of infectious disease models, e.g., in susceptible BALB/c
mice infected with 
 
Leishmania major
 
 the early IL-4 produc-
tion is responsible for the severe disease (for review see ref-
erence 9). In allergic diseases of humans there is a strong
correlation of the frequencies of IL-4–producing Th and
 
serum IgE concentrations (for review see reference 10). This
contrasts with helminth infections, e.g., with 
 
Trichuris muris
 
,
where IL-4 protects the host by induction of a Th2 re-
sponse. A protective role of Th-derived IL-4 was also dem-
onstrated in mouse models of autoimmune diseases such as
experimental allergic encephalomyelitis (EAE; reference 11)
and lupus-like autoimmune syndrome (12).
The pleiotropic activities of IL-4 are mediated by a high-
affinity receptor (
 
K
 
d
 
 
 
5
 
 20–300 pM), which is expressed in
low numbers (100–5,000) on a variety of cell types (13).
The majority of cells express IL-4R in association with the
common 
 
g
 
 chain (14), which is needed, at least in T cells,
for IL-4 signal transduction. Cloning of the cDNAs coding
for the mouse IL-4R (15, 16) and human IL-4R (17, 18)
and their expression in COS7 cells resulted in glycosylated
transmembrane proteins with a molecular mass of 140 kD.
The murine and human IL-4R share 
 
z
 
50% homology on
the amino acid level and both molecules share the two cys-
teine pairs and the WSXWS motif in their extracellular do-
main, which are characteristic for type I cytokine receptors.
In the case of the murine IL-4R, an additional cDNA derived
by alternative spliced mRNA coding for a 40 kD sIL-4R has
been identified (15).
Allelic variation was first characterized for Igs, HLA/
MHC-antigens, TCRs, and complement factors, but,
 
1
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: EAE, experimental allergic encephalomy-
elitis; s, soluble.
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meanwhile, this important evolutionary mechanism has
also been shown for a large number of other molecules.
The murine IL-2 is the first example of a cytokine encoded
by at least five distinct alleles comprising polymorphic IL-2
molecules differing in their biological activity for the prolif-
eration of human PBL and T cells (19). As shown recently,
the expression of a mutant allele of the chemokine receptor
5 in HIV-1–resistant Caucasian patients leads to a nonfunc-
tional receptor that reduces fusion or infection of cells by
primary monocytotrophic HIV-1 strains (20). Mice ho-
mozygous for a point mutation in the cytoplasmic domain
of Fas, which inhibits Fas signal transduction, develop lym-
phadenopathy and SLE-like autoimmune disease due to a
defect in Fas-mediated apoptosis (21). In the case of the
leptin receptor the mutant allele encodes a truncated recep-
tor unable to induce activation of STAT (signal transducer
and activator of transcription) proteins, causing obesity of
mice (22). Typically, these described allelic variations result
in the loss of function by major structural alterations of the
respective gene products, thereby causing different diseases.
In this work we present the first example for an allelic
variation within the type I cytokine receptor family. The
naturally occurring allotypes of the murine IL-4R differ
not only in their amino acid sequence, but also in their
functional properties. These allotypic differences may result
in divergent outcomes of IL-4–dependent immune re-
sponses in vivo
 
.
 
Materials and Methods
 
Mice.
 
Female mice of the inbred strains AKR/J, BALB/c,
C3H/HeN, C57BL/6, CBA, C.B-17/SCID, DBA/2, FVB/N,
and SJL/J were obtained from Charles River Labs. (Sulzfeld, Ger-
many) and used at 6–12 wk of age.
 
Cell Clones and Lines.
 
The BALB/c mouse–derived Th2
clone L1/1, specific for the protozoan parasite 
 
L. major
 
, was pro-
vided by M. Lohoff (Institute of Clinical Microbiology and Im-
munology, Erlangen, Germany; reference 23). The mouse Th
HT-2 and the human erythroleukemic cell line TF-1 (24) was
obtained from the American Type Culture Collection (Rock-
ville, MD). The human kidney cell line 293-EBNA was purchased
from Invitrogen (Leek, The Netherlands).
 
RNA Isolation, Reverse Transcription, and PCR.
 
After RNA ex-
traction from mouse spleen cells with acidic guanidinium thiocy-
anate (25), cDNAs were synthesized with reverse transcriptase
(Pharmacia Biotech, Freiburg, Germany) as previously described
(6). For PCR, cDNAs were amplified in a 40-
 
m
 
l reaction volume
containing 50 mM Tris-HCl, pH 8.3, 2.5 mM MgCl
 
2
 
, 1 mM of
each dNTP, 1 U of 
 
Taq
 
 (Pharmacia Biotech) or PFU (Stratagene,
Heidelberg, Germany) polymerase, and 100 nM of primers during
35 cycles (1 min denaturation at 94
 
8
 
C, 1 min annealing at 58
 
8
 
C,
and 1 min extension at 72
 
8
 
C). Primers used for PCR were as fol-
lows: (
 
a
 
) sense primer 1, 5
 
9
 
-GCAGGCACCTTTTGTGTC-
CCC-3
 
9
 
 (position 
 
2
 
97 to 
 
2
 
77), and antisense primer 2, 5
 
9
 
-CT-
CACCACCGCAGCCCCCAAGGTCA-3
 
9
 
 (position 624–648),
for the murine sIL-4R (product length 745 bp); and (
 
b
 
) primer 1
and antisense primer 3, 5
 
9
 
- CCCTGGCCTCAGCACAGAC-
CTC-3
 
9
 
 (position 2383–2404), for the transmembrane form of the
murine IL-4R (product length 2,501 bp). Samples were separated
on 1.5% agarose gels containing 0.2 
 
m
 
g/ml ethidium bromide.
 
Sequence Analysis.
 
Sequence analysis of cloned or PCR-
amplified sIL-4R or IL-4R cDNAs was performed using the dye
terminator cycle sequencing ready reaction kit (PE Applied Bio-
systems, Warrington, UK) as recommended by the manufacturer.
Primers used were as follows: in sense orientation, primer 1 and
primers 5
 
9
 
-GCCCCAGTGGTAATGTGAAGCCCC-3
 
9
 
 (posi-
tion 275–298), 5
 
9
 
-TCAACCAAGTACCCGCACTGGA-3
 
9
 
(position 814–835), 5
 
9
 
-GAGCTGGCTCCAGAGCAGCAGC-3
 
9
 
(position 1468–1489); and in antisense orientation, primer 2,
primer 3, and primers 5
 
9
 
-TCGGGAAGCTCAGCCTGGGTT-3
 
9
 
(position 470–490), 5
 
9
 
-TTCAGCAAGCAAGGCAGCAGC-3
 
9
 
(position 852–872), 5
 
9
 
-ATGAGATAGTCAAAGAGGACCTG-
TAGG-3
 
9
 
 (position 1060–1086), and 5
 
9
 
-CGGGCTTGGAG-
GCTCCTCTTCT-3
 
9
 
 (position 1506–1527).
 
Restriction Analysis.
 
The 745-bp PCR fragments obtained
from the sIL-4R cDNAs were restricted with the enzymes Eco-
47III or HhaI. Resulting fragments were analyzed on 1.5% aga-
rose gels containing 0.2 
 
m
 
g/ml ethidium bromide and compared
with the fragment sizes calculated with the Lasergene software
package (DNASTAR Inc., Madison, WI).
 
Analysis of Cell Culture Supernatants.
 
The supernatants of trans-
fected cells were analyzed by sandwich ELISAs. Seven indepen-
dently derived rat hybridomas (1046-570-2, 1046-957-14, 1046-
1273, 1046-1273-2, 1046-1658-13, 1046-1712, and 1046-1910)
and nine mouse hybridomas (999-31, 999-258, 999-461, 999-643,
999-707, 999-927, 999-1243, 999-1366, and 999-1378) were
raised after immunization of Lewis rats or BALB/c mice with pu-
rified recombinant C57BL/6 sIL-4R expressed in BHK-21 cells
(6) by applying standard techniques. The anti–IL-4R mAbs pro-
duced by these hybridomas were purified by affinity chromatog-
raphy with protein G–Sepharose (Pharmacia Biotech) and cou-
pled to the bottom of microtiter plate wells in a concentration of
5 
 
m
 
g/ml. Detection was performed with the rat mAb M1 (Gen-
zyme, Cambridge, MA) or with affinity-purified antiserum raised
from a rabbit immunized with recombinant murine sIL-4R. Al-
kaline phosphatase–coupled Abs goat anti–rat or donkey anti–
rabbit (Dianova, Hamburg, Germany) were used as secondary
Abs. The ELISAs were standardized using purified recombinant
murine sIL-4R (6) and had a working range of 40–2,000 pg/ml.
 
Murine IL-4R Expression Constructs.
 
cDNAs prepared from
Con A–stimulated (Sigma Chemical Co., Deisenhofen, Germany)
spleen cells of C57BL/6 or BALB/c mice were used as templates
for PCR with primers 1 and 2 for the sIL-4R or with primers 1
and 3 for the membrane-bound IL-4R. The products obtained
with C57BL/6 and BALB/c cDNA were subcloned and served
for the construction of sIL-4R-C57BL/6-BALB/c hybrid cDNAs
by use of the internal and plasmid-encoded EcoRI restriction
sites. For the C57BL/6-T49I sIL-4R construct, we applied the
PCR mismatch technique using the IL-4R primer 1 and the anti-
sense primer 5
 
9
 
-TTCCTCGGGATGCATATGAGGTTTTC-
AGAG-3
 
9
 
 (position 132–161; underlined nucleotide indicates the G
to A exchange) to introduce a point mutation leading to the Thr49
to Ile substitution in the C57BL/6 sIL-4R peptide. The 5
 
9
 
-region
of the wild-type sIL 4R cDNA was substituted for the mutated
sequence using the NsiI restriction site. Resulting fragments were
cloned into the eukaryotic expression vector pCEP4 (Invitrogen).
The 2,501-bp cDNAs encoding the transmembrane IL-4Rs were
cloned into the eukaryotic expression vector pM5neo, provided by
W. Ostertag Heinrich-Pette-Institute (Hamburg, Germany).
 
Transfection and Cell Cloning.
 
15 
 
m
 
g of purified plasmid DNA
was electroporated into 10
 
7
 
 293-EBNA or TF-1 cells in 0.8 ml of
medium (Click’s RPMI 1640 [Life Technologies, Eggenstein, Ger-
many], 2 mM 
 
l
 
-glutamine, 10 mM Hepes, 100 
 
m
 
g/ml penicillin, 
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60 ng/ml streptomycin, 13 mM NaHCO
 
3
 
 and 5 
 
3
 
 10
 
2
 
5
 
 M 2-ME)
supplemented with 10% (vol/vol) FCS (Biochrom, Berlin, Ger-
many) at 900 
 
m
 
F and 260 V in an Easyject electroporation unit
(Eurogentec, Seraing, Belgium). The selection of sIL-4R–trans-
fected 293-EBNA cells was started after 36 h by addition of hy-
gromycin (Calbiochem, Bad Soden, Germany) to a final concen-
tration of 0.3 mg/ml. Cell supernatants were analyzed for their
sIL-4R contents 3 wk after electroporation. Stably transfected
TF-1 cells were selected by cultivation in the presence of 1 mg/ml
G418 (Calbiochem) for 2 wk and subjected to single cell cloning.
 
Purification of Soluble Receptors.
 
sIL-4R from supernatants of
transfected 293-EBNA cells was affinity-purified using the rat
mAb 1046-1712 coupled to an 
 
N
 
-hydroxysuccinimide–activated
HiTrap column (Pharmacia Biotech AB, Uppsala, Sweden). The
eluted sIL-4R proteins were dialyzed and concentrated in Cen-
trisart-C30 Microcentrifuge Filters (Sartorius AG, Goettingen,
Germany). The purity of the IL-4R preparations was verified by
silver-stained SDS-PAGE and the concentration was determined
by ELISA and the AminoQuant Series II derivatization method
(Hewlett Packard, Waldbronn, Germany), performed by Dr. J.
Bernhagen (Fraunhofer Institut, Stuttgart, Germany) according to
the manufacturer’s recommendations.
 
Flow cytometry.
 
Transfected TF-1 cells were analyzed by flow
cytometric analysis on a FACScan
 
Ò
 
 with Lysis software. IL-4R was
detected by indirect immunofluorescence with M1, 1046 (rat) or
999 (mouse) mAbs as primary Abs and FITC-conjugated goat
anti–rat Ab or rabbit anti–mouse Ab (Dianova) as secondary Abs.
 
SDS-PAGE and Western Blotting.
 
TCA-precipitated superna-
tants or column elutions containing sIL-4R were separated under
reducing conditions on a 15% SDS-PAGE gel. Immunodetection
of IL-4R on nitrocellulose blots was performed with a rabbit an-
tiserum followed by a swine anti–rabbit Ig conjugated with
horseradish peroxidase (Dianova) and the enhanced chemilumi-
nescence Western blotting system (Amersham, Braunschweig,
Germany).
 
Cell Proliferation Assays.
 
The murine Th cells L1/1 and HT-2
were incubated in medium for 48 h with recombinant murine
IL-4 (IC Chemikalien, Ismaning, Germany) in the presence or ab-
sence of different concentrations of sIL-4R before [
 
3
 
H]thymidine
was added for the final 16 h of culture. The cells were harvested
and [
 
3
 
H]thymidine incorporation was measured in a 
 
b
 
 counter
(Berthold, Munich, Germany). The ED
 
50
 
 values were calculated
using Prism software (GraphPAD Software for Science, San Di-
ego, CA).
 
Surface Plasmon Resonance.
 
Measurements of receptor–ligand
interactions were performed using a surface plasmon resonance
detector (Pharmacia Biotech AB). Murine IL-4 was immobilized
to a nonneutralizing anti–IL-4 mAb, which was coated to a CM5
sensor chip as described by the manufacturer (Pharmacia Biotech
AB). The association and dissociation of the C57BL/6 and BALB/c
sIL-4R in HBS buffer (10 mM Hepes, 150 mM NaCl, 3.4 mM
EDTA, and 0.005% surfactant P20, pH 7.4) were analyzed at a
flow rate of 5 
 
m
 
l/min at 25
 
8
 
C. Five different protein concentra-
tions were analyzed for each sIL-4R preparation. Calculation of
the rate constants was performed with the attendant evaluation
software.
 
Iodination of Murine IL-4.
 
5 
 
m
 
g of recombinant murine IL-4
was iodinated as described by Lowenthal et al. (13) using Io-
dogen-coated (Pierce Chemical Co., Rockford, IL) coated glass
tubes. Iodinated IL-4 (
 
125
 
I–IL-4) was repurified by use of an anti–
IL-4 affinity column and the concentrations of the IL-4 prepara-
tions were determined by ELISA. The specific activity of the
 
125
 
I–IL-4 was 
 
z
 
9 
 
3
 
 10
 
14
 
 cpm/mmol.
 
125
 
I–IL-4–binding Assays.
 
Binding of 
 
125
 
I–IL-4 to murine IL-4R
expressed on human TF-1 cells was measured according to the
methods described by Lowenthal et al. (13). For the equilibrium
binding analysis, aliquots of 5 
 
3
 
 10
 
5
 
 cells were incubated in the
presence of different concentrations of 
 
125
 
I–IL-4 in a final volume
of 200 
 
m
 
l in microfuge tubes at 4
 
8
 
C until equilibrium had been
achieved (90 min). To separate nonbound 
 
125
 
I–IL-4 from cell-
bound 
 
125
 
I–IL-4, the reaction mixture was centrifuged through an
oil gradient. Nonspecific binding was determined by addition of a
200-fold excess of unlabeled IL-4 and was subtracted from spe-
cific binding. For the dissociation kinetics, the IL-4R–transfected
cells were incubated in the presence of 1,200 pM 
 
125
 
I–IL-4 for 90
min at 4
 
8
 
C to obtain receptor saturation. Cells were then washed
twice and ligand dissociation was allowed to proceed in medium
at 4
 
8
 
C. Aliquots of 5 
 
3
 
 10
 
5
 
 cells were taken at the indicated times
and bound IL-4 was measured. Obtained data were calculated us-
ing Prism software.
 
Results
 
The Newly Identified BALB/c IL-4R Allotype Contains 18
Base Substitutions Leading to Eight Mainly Nonconservative
Amino Acid Changes.
 
Sequence analysis was performed
with cloned or PCR-derived cDNAs coding for the trans-
membrane IL-4R or sIL-4R, respectively. The cDNAs de-
rived from BALB/c mice were not identical in their base
sequence, compared to the published data obtained from
the T cell line CTLL or mast cell line MC/9 established from
C57BL/6 mice (15, 16). We found 18 base substitutions,
which were reproducibly detected in cDNAs obtained in-
dependently either from five BALB/c mice or the murine
Th2 line L1/1, established from a BALB/c mouse (Table
1). Sequencing revealed no differences between C57BL/6,
C3H, CBA, DBA/2, and FVB/N mice, whereas the mouse
strains AKR/J and SJL/J showed the same base variations
found in the extracellular part of the BALB/c IL-4R.
The predicted translated product of the BALB/c IL-4R
cDNA varies in eight amino acids, compared to the pub-
lished C57BL/6 IL-4R amino acid sequence. Three of the
substitutions are located in the extracellular and five in the
cytoplasmic part of the IL-4R protein (Table 1). The sub-
stitutions at positions 49 and 309 have been previously ob-
served in genomic DNA derived from BALB/c mice (26).
Of special interest are (
 
a
 
) the extracellular substitution of
Cys34 to Arg leading to the loss of a potential disulfide
bond partner in the BALB/c IL-4R and (
 
b
 
) the Thr49 to
Ile substitution abrogating a potential 
 
N
 
-glycosylation site
(see below). Due to the charges of the substituted amino
acids, the predicted isoelectric point of the sIL-4R is shifted
from 5.16 to 5.38 in the BALB/c allotype.
We also sequenced the BALB/c cDNA of the common
 
g
 
 chain, which is also a component of the functional IL-4R
complex (14). Compared to the published sequence, no
base substitutions in the coding region of the common 
 
g
chain were present (data not shown), showing that the allo-
typic variation in the BALB/c IL-4R complex is confined
to one receptor chain.
Since we were interested in whether there are allelic IL-
4R variants in other mammalian species, e.g., humans, the1422 Interleukin 4 Receptor Allotype
cDNAs coding for the extracellular IL-4R domain from
the human cell lines TF-1 (24), HUT-78, HeLa, and Jurkat
(all obtained from the American Type Culture Collection)
were also sequenced. Only one A to G transition in the HeLa,
Jurkat, and TF-1 cDNA was found, compared to the published
sequence from T-22 cells (17, 18), leading to the conserva-
tive amino acid substitution Ile to Val at position 50 (data
not shown).
IL-4R Alleles Are Detectable by DNA Restriction Analy-
sis. The PCR-amplified sIL-4R cDNAs from different
mouse strains were digested with the restriction enzymes
Eco47III or HhaI, and the resulting fragments were size
compared. Except for the PCR products from BALB/c
and SCID mice, all tested DNA fragments were digested by
Eco47III, yielding two fragments of 573 and 172 bp (Fig.
1). In the case of the BALB/c and SCID sIL-4R cDNAs, the
T to C base substitution at position 78 led to the loss of the
restriction site and to an undigestable DNA fragment of
745 bp. Digestion of PCR products from C57BL/6-type
cDNAs with HhaI resulted in three fragments of 449, 170,
and 126 bp, whereas the BALB/c and SCID cDNAs
yielded four fragments of 359, 170, 126, and 90 bp due to
an additional HhaI restriction site at position 168 (T to C
substitution).
Allotype-dependent Binding and Epitope Mapping of mAbs
Specific for the Extracellular Part of the IL-4R. A panel of mAbs
obtained either by immunization of BALB/c mice with the
recombinant C57BL/6 IL-4R or from similarly immu-
nized rats was analyzed with regard to their IL-4R binding
characteristics. mAbs were coupled to microtiter plates and
the IL-4R ELISAs were developed with polyclonal rabbit
Abs. While all of the murine mAbs were allotype specific,
recognizing the C57BL/6-type IL-4R, but not the IL-4R
of BALB/c, AKR/J, and SJL/J mice, the rat mAbs did not
distinguish between IL-4Rs obtained from the different in-
bred strains of mice (Fig. 2). Thus, these binding data ob-
tained with cell culture supernatants as well as sera (data not
shown) confirmed the allotypic differences deduced from
the cDNA sequences. To map the allotype-specific binding
epitopes of the different murine mAbs, we cloned C57BL/6,
BALB/c, and C57BL/6-BALB/c-hybrid sIL-4Rs and ex-
pressed them in 293-EBNA cells. The two hybrid recep-
tors, C57BL/6-C34R-T49I and C57BL/6-M168T, were
constructed using the internal restriction site EcoRI as in-
dicated in Fig. 3. The PCR mismatch technique was used
to introduce a single point mutation in the C57BL/6 sIL-4R
cDNA leading to the C57BL/6-T49I sIL-4R.
Summarizing the mAb binding patterns, one-third of the
allotype-specific mAbs (three out of nine) was dependent
on the presence of Cys34, while the other mAbs were de-
pendent on Met168. Interestingly, none of the allotype-
specific mAbs appeared to be influenced by Thr49 and none
of them displayed IL-4–neutralizing capacity (Table 2).
We also analyzed seven rat mAbs, which showed no de-
tectable differences in their binding activity for all sIL-4R
constructs (Table 2 and data not shown). Importantly, the
binding behavior of the commercially available mAb M1 was
quantitatively different for the two tested IL-4R allotypes:
this mAb displayed threefold reduced OD410 values in the
ELISAs over a broad concentration range when BALB/c or
Table 1. Differences in the Nucleotide and Amino Acid Sequence 
Comparing the IL-4Rs of C57BL/6 and BALB/c Mice
cDNA Peptide
Base* C57BL/6 BALB/c C57BL/6 BALB/c aa‡
Extracellular region
78 T C
100 T C Cys Arg 34
105 A G
146 C T Thr Ile 49
165 T C
174 T C
213 A G
447 A T
503 T C Met Thr 168
Cytoplasmic region
861 T C
926 T C Leu Pro 309
945 A G
1046 A G Asn Ser 349
1071 A G Ile Met 357
1248 A G
1340 G A Gly Asp 447
1802 A G Asp Gly 601
2157 C T
*Numbers indicate the positions of the base exchanges counted from
the first nucleotide coding for the mature IL-4R.
‡Numbers indicate the positions of the amino acid substitutions in the
mature IL-4R peptide. The sequence data of the BALB/c IL-4R are avail-
able from EMBL/GenBank/DDBJ under accession number AF000304.
Figure 1. Restriction analysis of sIL-4R cDNAs. The sIL-4R cDNAs
of the different mouse strains indicated were PCR-amplified, gel-puri-
fied, and digested with the enzymes Eco47III or HhaI. Resulting frag-
ments were analyzed on a 1.5% agarose gel. The pUC Mix Marker (Fer-
mentas AB, Vilnius, Lithuania) was used for the determination of the
fragment sizes.1423 Schulte et al.
C57BL/6-T49I sIL-4Rs were compared with equivalent
concentrations of the C57BL/6 IL-4R type in contrast
to measurements with the polyclonal antiserum (data not
shown). Thus, the sIL-4R quantification by this mAb is
critically dependent on the presence of Thr49. The fact
that M1 is the only neutralizing mAb of all tested antibod-
ies leads to the hypothesis that Thr49 is either directly or
indirectly involved in IL-4–IL-4R interactions. According
to the model of human IL-4R (27), the substitutions at po-
sition 34 and 49 are located near the postulated IL-4–bind-
ing region of the IL-4R, whereas the Met168 is located
more proximal to the cell surface.
To investigate whether the binding epitopes on the
transmembrane IL-4R are accessible for the mouse mAbs,
Figure 2. Comparison of sIL-4R ELISAs applying rat or mouse mAbs.
Sandwich ELISAs were performed with either the rat mAb 1046-957-14
(white bars) or the mouse mAb 999-1243 (black bars) coupled to microtiter
plates. Spleen cells of the indicated mouse strains were cultured for 48 h
in the presence of 7.5 mg/ml Con A and the supernatants were analyzed
in the ELISAs. Bound sIL-4R was detected with affinity–purified poly-
clonal IL-4R–specific rabbit Abs followed by donkey anti–rabbit Ig cou-
pled to alkaline phosphatase.
Figure 3. Murine sIL-4R constructs designated for the expression in
293-EBNA cells. Boxes represent the coding regions of the sIL-4Rs de-
rived from C57BL/6 (black) or from BALB/c (white) mice. The amino ac-
ids differing between the C57BL/6 and BALB/c sequences are indicated.
The names of the constructs include the substituted amino acids in the
C57BL/6 sIL-4R and their position in the mature peptide. See Materials
and Methods for details of the cloning strategies.
Table 2. Binding Epitopes of IL-4R–specific mAbs
ELISA*
Flow cytometry‡
Epitope
dependent on§
Neutralization of
IL-4 function¶ C57BL/6 BALB/c
C57BL/6-
C34R-T49I
C57BL/6-
M168T
C57BL/6-
T49I C57BL/6 BALB/c
Mouse mAb
999-31 Yes No No Yes Yes Yes No Cys34 No
999-258 Yes No Yes No Yes No No Met168 No
999-461 Yes No No Yes Yes Yes No Cys34 No
999-643 Yes No Yes No Yes No No Met168 No
999-707 Yes No Yes No Yes No No Met168 No
999-927 Yes No Yes No Yes Yes No Met168 No
999-1243 Yes No Yes No Yes No No Met168 No
999-1366 Yes No No Yes Yes Yes No Cys34 No
999-1378 Yes No Yes No Yes No No Met168 No
Rat mAb
1046-957-14 Yes Yes Yes Yes Yes Yes Yes — No
1046-1658-13 Yes Yes Yes Yes Yes No No — No
M1 Yes Yesi Yesi Yes Yesi Yes Yes Thr49i Yes
*ELISA data obtained with the different sIL-4R constructs as designated in Fig. 3. Supernatants of transfected 293-EBNA cells were tested.
‡Flow cytometry was performed with transfected TF-1 cells expressing IL-4R allotypes.
§Amino acids of the C57BL/6 IL-4R located in the binding epitopes of the mouse mAbs as judged by the ELISA measurements.
¶The neutralizing function of the mAbs was detected by their capability to inhibit the IL-4–induced proliferation of HT-2 cells.
iBinding of mAb M1 was present but the OD values in the ELISA were three-fold reduced as compared to the detection with a polyclonal antiserum
raised against sIL-4R.1424 Interleukin 4 Receptor Allotype
FACSÒ analyses of transfected TF-1 cells were performed.
The transfectants expressed functionally active C57BL/6 or
BALB/c transmembrane IL-4Rs, since these factor-depen-
dent human cells were grown with species-specific murine
IL-4 for several months (data not shown). All three Cys34-
dependent mAbs, but only one of six Met168-dependent
mAbs, bound to the C57BL/6 IL-4R at the cell surface,
whereas the BALB/c IL-4R was not recognized (Table 2
and Fig. 4). The mAb M1 was capable of staining both IL-4R
allotypes expressed on the cell surface (Fig. 4). These results
show that the Cys34-containing epitope is easily accessible
whereas the region around Met168 may be more hidden
through steric interactions with the cell membrane, with
the IL-4R itself, or with other cell surface molecules. Two
of the seven rat mAbs were able to bind to the cell surface
IL-4R, but in an allotype-independent manner as expected
(Table 2 and data not shown).
The BALB/c sIL-4R Lacks One N-glycosylation Site.
The properties of the sIL-4R allotypes were compared in
Western blot analyses with supernatants of transfected 293-
EBNA cells. Compared to the C57BL/6 sIL-4R, the BALB/c
sIL-4R and the mutated sIL-4R construct C57BL/6-T49I
show an increased mobility on SDS-PAGE (Fig. 5 A) and
share a Thr49 to Ile substitution. This exchange leads to
the loss of a potential N-glycosylation site by inactivation
of the recognition sequence (Asn47-X48-Thr49) commonly
used by oligosaccharyl transferases to fix the glycan to Asn
as illustrated in Fig. 5 B. When we used N-glycanase to de-
glycosylate affinity-purified C57BL/6 and BALB/c sIL-4R,
the differences between the migration behavior of these
molecules vanished (Fig. 5 C). These findings and the mi-
gration behavior of the C57BL/6-T49I sIL-4R strongly ar-
gue for N-glycosylation of Asn47, which occurs only in the
C57BL/6 but not in the BALB/c IL-4R allotype.
The Substitution of Thr49 to Ile Results in a Reduced IL-4–neu-
tralizing Capacity of the BALB/c sIL-4R. Since the C57BL/6
and BALB/c sIL-4R display different biochemical proper-
ties, we addressed the question of whether the allotypic dif-
ferences also result in functional changes. Therefore, the
sIL-4R proteins were analyzed for their capacity to inhibit
IL-4–induced proliferation of the Th2 clone L1/1 and HT-2
cells. The dose–response curves clearly revealed a dimin-
ished IL-4–neutralizing effect of the BALB/c sIL-4R when
compared to the C57BL/6 sIL-4R, irrespective of the cell
type used (Fig. 6 A and B). The calculated ED50 values ob-
tained from seven experiments performed with different
sIL-4R preparations averaged 640 6 158 pM for the
C57BL/6 and 1,650 6 193 pM for the BALB/c sIL-4R.
Interestingly, the C57BL/6-T49I sIL-4R construct dis-
played a dose–response curve (Fig. 6 A and B) and an ED50
value (1,370 6 243 pM) very similar to that of the BALB/c
sIL-4R. This indicates that the substitution of Thr49 and
the resulting loss of N-glycosylation at this part of the IL-4R
causes the allotypic differences of IL-4 neutralization.
Purified Recombinant C57BL/6 and BALB/c sIL-4R Allo-
types Differ in their Association and Dissociation Constants for
IL-4. To directly analyze the IL-4/IL-4R interactions,
biomolecular interaction analysis was performed using the
technique of surface plasmon resonance. The kinetics re-
Figure 4. Flow cytometric analysis of IL-4R allotypes expressed on hu-
man TF-1 cells. Transfected TF-1 cells stably expressing the transmem-
brane IL-4R of C57BL/6 or BALB/c mice were stained with the rat
mAb M1 or the mouse mAb 999-461, respectively. Fluorescence inten-
sity of the background staining with the FITC-conjugated secondary Abs
alone (white graphs) or the specific binding in the presence of the primary
mAbs (black graphs) was determined by use of a FACScanÒ.
Figure 5. Analysis of the glycosylation of different sIL-4R variants. (A)
Western blot of sIL-4R variants. Supernatants of transfected 293-EBNA
cells expressing the C57BL/6, BALB/c, or C57BL/6-T49I sIL-4Rs were
TCA-precipitated and separated on a 15% SDS-PAGE gel. Proteins were
blotted onto nitrocellulose and IL-4R bands were detected with an IL-
4R–specific polyclonal antiserum and visualized by enhanced chemilumi-
nescence. (B) The potential N-glycosylation site of the C57BL/6 sIL-4R
was absent in the BALB/c sIL-4R. The amino acids Asn47-Leu48-Thr49
found in the C57BL/6 sIL-4R (black box) represent an N-glycosylation
site, which is abrogated in the BALB/c sIL-4R by the Thr49 to Ile substi-
tution (white box). Threonins, which can be potentially O-glycosylated,
are indicated. (C) SDS-PAGE of affinity-purified C57BL/6 and BALB/c
sIL-4R allotypes. Purified sIL-4Rs were treated with (1) or without (2)
N-glycanase for 16 h at 378C. Samples were separated on a 15% SDS-
PAGE gel and silver stained. (A and C) Molecular mass markers are indi-
cated on the left.1425 Schulte et al.
vealed a twofold increased association rate (Kon) and a
slightly increased dissociation rate (Koff) for the BALB/c
sIL-4R in comparison to the C57BL/6 sIL-4R. Table 3
summarizes the data obtained with independently purified
sIL-4R preparations. The affinity constant (Kd), which is de-
fined as the quotient of Koff/Kon, revealed a relatively low af-
finity of both sIL-4R allotypes for IL-4 with this type of
measurement.
Cell Surface BALB/c IL-4R Complexes Show a Markedly
Increased Koff. Since the experiments described thus far
were performed exclusively with soluble and most probably
monomeric IL-4R molecules, we set out to analyze the
ligand-binding characteristics of IL-4R complexes expressed
at the cell surface. Equilibrium binding analysis was per-
formed with transfected human TF-1 cells expressing func-
tionally active C57BL/6 or BALB/c allotypic IL-4Rs. The
resulting saturation binding curves and Scatchard plots re-
vealed Kd values of 370 and 410 pM for the C57BL/6 and
BALB/c IL-4Rs, respectively, which were expressed in
comparable numbers (17,000–22,000 molecules/cell) on
the transfected TF-1 cells (Fig. 7 A). Importantly, the ki-
netic measurements revealed a markedly enhanced dissoci-
Figure 6. Inhibition of IL-4–induced proliferation by different sIL-4R
variants. The Th L1/1 (A) or HT-2 (B) were incubated with 2 ng/ml re-
combinant murine IL-4 and serial diluted concentrations of C57BL/6,
BALB/c, or C57BL/6-T49I sIL-4Rs, respectively. After 48 h [3H]-thy-
midine was added and 16 h later the cells were harvested and radioactivity
was measured in a b counter. Sigmoidal dose–response curves were cal-
culated for each set of data.
Table 3. Association (Kon) and Dissociation (Koff) Rates of sIL-4R 
Allotypes Evaluated with Surface Plasmon Resonance
sIL-4R Kon (M21 s21) Koff (s21) Kd (nM)
C57BL/6 Exp. 1 5.06 3 104 1.48 3 1023 29.25
Exp. 2 4.33 3 104 1.30 3 1023 30.02
BALB/c Exp. 1 8.73 3 104 2.07 3 1023 23.71
Exp. 2 8.54 3 104 2.08 3 1023 24.36
Binding of sIL-4R allotypes to immobilized IL-4 and resulting Kon and
Koff rates obtained with two independent protein preparations (Exp. 1
and 2). The affinity constant (Kd) is calculated by the equation Koff/Kon.
Figure 7. 125I–IL-4–binding to the IL-4R allotypes expressed as cell
surface molecules. Ligand binding analysis was performed with human TF-1
cells expressing C57BL/6 or BALB/c IL-4R. (A) Equilibrium binding
studies. Cells were incubated with various concentrations of 125I–IL-4 for
90 min at 48C and assayed for binding as described in Materials and Meth-
ods. Data are corrected for nonspecific binding and are presented as satu-
ration binding curve or Scatchard plot (inset). (B) Dissociation of IL-4
from the transmembrane receptors. Transfected TF-1 cells were incubated
in the presence of 1.2 nM 125I–IL-4 for 90 min at 48C, washed twice, resus-
pended in medium, and incubated at 48C. Aliquots of 5 3 105 cells were
taken at the indicated time points and the amount of IL-4 still bound to
the cell surface was determined. The calculated Koff values for this experi-
ment are indicated.1426 Interleukin 4 Receptor Allotype
ation rate for the BALB/c IL-4R (Fig. 7 B), while the asso-
ciation rates were similar (200–260 3 106 M21 min21). In
several experiments, the calculated Koff values were in the
range of 7–16-fold faster for the BALB/c IL-4R than for
the C57BL/6 IL-4R.
Discussion
We have shown that the murine IL-4R exists in differ-
ent allotypes in inbred strains of mice. To our knowledge,
this represents the first example of a type I cytokine recep-
tor encoded by two different alleles. These IL-4R allotypes
differ in eight amino acids which result in differences in
their functional properties concerning IL-4–binding by the
transmembrane IL-4R as well as IL-4–neutralizing activity
by the sIL-4R. This report also provides evidence that
N-glycosylation at Asn47 of the IL-4R influences IL-4
binding. The established IL-4R allotype-specific mAbs and
the PCR-based restriction analysis represent new tools to
analyze the correlation between IL-4R allotype expression
and disease phenotypes in mice.
It appears very unlikely that the newly discovered IL-4R
allele arose spontaneously during the establishment or con-
tinuous breeding of the BALB/c inbred strain. First, the
occurrence of 18 mutations within only 80 yr since the es-
tablishment of the BALB/c strain in 1913 is far from the
known mutation rate of eukaryotic genes in evolution
which is z1 in 105 generations. Second, the fact that the
sIL-4R sequences of AKR/J and SJL/J mice are identical
to the allelic BALB/c IL-4R variant argue against a recent
emergence of the IL-4R alleles, since no connection be-
tween dealers or breeders who established these three strains
were found (Mouse Genome Database [MGD], Mouse
Genome Informatics, The Jackson Laboratory [Bar Harbor,
ME]. World Wide Web URL: http://www.informat-
ics.jax.org/). Since the sIL-4R cDNAs of C3H, CBA,
DBA/2, and FVB/N are identical to the published se-
quence, we speculate that the two defined murine allelic
IL-4R variants existed before the establishment of inbred
strains of mice and that a selective pressure had stabilized
these IL-4R variants. At least in the molecules participating
at the formation of the high-affinity IL-4R complex, the
allelic variation of the IL-4R appears to be unique, because
no sequence variation was found for the common g chain.
Our very limited analysis of human IL-4R sequences
showed only a minor allotypic variation leading to a con-
servative amino acid substitution (Ile to Val), which is most
likely irrelevant for the functioning of the human IL-4R.
Nevertheless, more intense analysis of human IL-4R cDNAs
is necessary to clarify whether functionally important IL-4R
allotypes exist. Finding evidence of IL-4R allotypes in the
human population and correlation with a disease such as al-
lergy would be of obvious interest.
Focusing on the extracellular IL-4R domain the Cys34
substitution for the basic amino acid Arg in the BALB/c
IL-4R alters not only the charge of the protein but may
also lead to the loss of a potential disulfide bond. However,
we consider the latter possibility unlikely because (a) the
Cys34 is not conserved between the rat, human, and mouse
IL-4Rs, and (b) the currently available model of the human
IL-4R (27) does not display a disulfide bond at this part of
the molecule. Two other exchanges in the extracellular part
of the IL-4R lead to the substitution of a polar Thr against
the nonpolar amino acids Ile or Met. However, the most
important finding of our study is the fact that Asn47 is
N-glycosylated in the C57BL/6 IL-4R and that the loss of
this glycosylation site found either naturally in the BALB/c
IL-4R or experimentally introduced by a single point mu-
tation (C57BL/6-T49I variant) is responsible for the nearly
threefold-reduced IL-4–neutralizing capacity of these IL-4R
variants. Thus, we speculate that the glycan at Asn47 of the
C57BL/6 IL-4R is either stabilizing the tertiary structure
of the ligand-binding domain or influencing its accessibility
for IL-4. Analogous findings have been reported for human
CD2 where the elimination of the N-linked glycan, situ-
ated outside of the CD2/CD58 interface, resulted in a loss
of the CD58-binding activity of CD2 (28). In the case of
the human IFN-g receptor, inhibition of N-linked glyco-
sylation blocked human IFN-g–binding capacity of the cell
surface receptor molecules (29). A stringent requirement
for N-linked glycosylation has also been shown for the ba-
sic fibroblast growth factor receptor (30). Moreover, at least
partial glycosylation of the receptors for the epidermal growth
factor (31) or insulin (32) was necessary to acquire ligand-
binding capacity. On the other hand, inhibition of N-linked
glycosylation or deglycosylation of LH receptors (33) or
b-adrenergic receptors (34) did not influence ligand-bind-
ing properties.
Since none of the IL-4R allotype-specific mAbs block
binding of IL-4, the allotypic amino acids appear not to be
situated directly in the IL-4 binding groove of the IL-4R.
However, like IL-4, the neutralizing rat mAb M1 displayed
a threefold reduced binding to the sIL-4Rs lacking the
N-glycosylation at Asn47. This is in line with the assump-
tion that this mAb binds directly to the ligand-binding do-
main of the IL-4R, which is influenced by carbohydrate side
chains.
The reduced IL-4–neutralizing capacity of the BALB/c
sIL-4R may be best explained by the increased dissociation
rate as compared to the C57BL/6 sIL-4R, as previously
shown for other cytokine receptors. For example, the de-
creased IL-2–neutralizing ability of the soluble IL-2R b
chain alone when compared to b/g chain heterodimers is
due to a higher dissociation rate (35). Although surface
plasmon resonance measurements revealed a slightly faster
dissociation rate for the BALB/c IL-4R, these differences
were much more pronounced when receptor complexes
expressed on the cell membrane were analyzed. This may
be due to the different experimental settings (immobilized
receptor versus immobilized ligand) and/or the participa-
tion of the common g chain on the cell membrane leading
to slower kinetics and higher Kd values.
Thus far, we have not analyzed the functional conse-
quences of the five allotypic amino acid substitutions found
in the cytoplasmic region of the murine IL-4R. Since these
include two nonconservative substitutions in a domain crit-1427 Schulte et al.
ically involved in IL-4R signaling (Gessner, A., and M.
Röllinghof, unpublished data) the effect of the intracellular
IL-4R differences is in the center of ongoing investigations.
In the 10 yr since the original description of Th1 and
Th2, the study of the frequencies of these populations and
their role in various infectious and autoimmune diseases has
become a major focus. The clinical outcome of several dis-
eases is critically dependent on the type of Th response
dominating and thereby controlling the effector functions
of other cell types such as macrophages and B cells. The
development of Th2 is induced by IL-4 (for review see ref-
erence 36), which dominates over IL-12, the main inducer
of Th1 development, when both cytokines are present dur-
ing the early Th differentiation (37). For BALB/c mice, the
existing data suggest a defect in CD41 subset priming such
that IL-4 is oversensitizing or overabundant. Several exper-
imental findings support this hypothesis. First, during the
early phase of L. major infection, there is a higher expres-
sion of IL-4 in BALB/c mice compared to other inbred
strains, which is not downregulated during the subsequent
weeks (38, 39). Second, priming of ovalbumin-specific
TCR-transgenic CD41 T cells in vitro in the absence of
exogenously added cytokines caused a much more Th2-
like phenotype in cells on the BALB/c background than
with precursors from the B10.D2 background (40). Third,
using such TCR transgenic T cells, only 200 U/ml of IL-4
could drive full Th2 differentiation in vitro when cells
were on the BALB/c background (41) in contrast to TCR
transgenic T cells from B10.A mice, which required five-
fold more IL-4 for Th2 differentiation (42).
The inherited differences in the capability to generate ei-
ther a Th1 or Th2 response in vivo appear to be multigen-
ically controlled (43, 44). In the case of EAE, the clinical
severity correlates with the expression of Th1 cytokines
(45) and the induction of Th2 results in clinical protection
(11). Microsatellite exclusion mapping of backcrossed mice
revealed that the disease susceptibility for EAE was most
strongly linked to mouse chromosome 7 (P ,0.001; refer-
ence 44). Since the murine IL-4R gene is located on chro-
mosome 7, it will be interesting to analyze the contribution
of the IL-4R allotypes defined in our study to the Th1/
Th2 development and disease susceptibility in this model of
autoimmunity. In lupus-like renal disease of New Zealand
White mice, another model of autoimmunity, one of the
most strongly associated loci was also found to be located
on mouse chromosome 7 (P ,0.008) within an interval
containing the IL-4R gene (46).
For several reasons we speculate that the allotypic differ-
ences of the murine IL-4R may influence the function of
IL-4 in vivo in several ways partially causing the IL-4 hy-
perresponsiveness of the BALB/c mouse. First, the reduced
neutralizing activity of the newly identified IL-4R allotype
could be of importance in situations with a molar excess of
the sIL-4R to the ligand (less efficient IL-4 antagonist).
Second, during the early phase of a specific T cell response,
when the concentrations of IL-4 exceed those of the sIL-
4R, the sIL-4R may act as a transport molecule for IL-4
(47). The higher dissociation rate of the BALB/c sIL-4R
allotype could result in a more rapid release of IL-4 in mi-
croenvironments with IL-4–responsive cells, prolonging the
half-life of IL-4 (transporter function). Third, the enhanced
dissociation rate of IL-4 from the membrane-bound BALB/c
IL-4R as detected in this study could result in more recep-
tor signals per IL-4 molecule, since the shorter contact time
of IL-4 might enable the ligand to contact more receptor
molecules in a given period of time. In sum, the resulting
inborn differences of IL-4 responsiveness might contribute
to the observed differential tendencies of inbred mice to
generate either a Th1- or a Th2-dominated immune re-
sponse.
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